

# Anne Lynn S Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3769309/publications.pdf>

Version: 2024-02-01

83  
papers

7,170  
citations

126858

33  
h-index

64755

79  
g-index

84  
all docs

84  
docs citations

84  
times ranked

8717  
citing authors

#	ARTICLE	IF	CITATIONS
1	A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 339-344.	0.6	19
2	Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. <i>PLoS ONE</i> , 2022, 17, e0262151.	1.1	7
3	Paired Transcriptomic and Proteomic Analysis Implicates IL-1 $\beta$ in the Pathogenesis of Papulopustular Rosacea Explants. <i>Journal of Investigative Dermatology</i> , 2021, 141, 800-809.	0.3	12
4	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 848-857.	5.1	150
5	Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. , 2021, 9, e002757.		46
6	A rare case of <i>Wohlfahrtiimonas chitiniclastica</i> infection in California. <i>JAAD Case Reports</i> , 2021, 17, 55-57.	0.4	1
7	Alterations of Immune and Keratinization Gene Expression in Papulopustular Rosacea by Whole Transcriptome Analysis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1100-1103.e4.	0.3	10
8	Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. <i>British Journal of Dermatology</i> , 2020, 182, 1369-1378.	1.4	104
9	Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. <i>JAAD Case Reports</i> , 2020, 6, 819-821.	0.4	2
10	An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. <i>British Journal of Dermatology</i> , 2020, 183, 942-943.	1.4	13
11	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
12	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2020, 21, 294-305.	5.1	304
13	A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1807-1809.	0.6	6
14	Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10018-10018.	0.8	34
15	Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10033-10033.	0.8	11
16	A phase I study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10080-TPS10080.	0.8	2
17	Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. <i>Nature Biotechnology</i> , 2019, 37, 925-936.	9.4	622
18	Clonal replacement of tumor-specific T cells following PD-1 blockade. <i>Nature Medicine</i> , 2019, 25, 1251-1259.	15.2	974

#	ARTICLE	IF	CITATIONS
19	Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2263-2271.e5.	0.3	24
20	Reply to: "Use of immortal time within survival analysis". <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e19-e20.	0.6	7
21	Enhancer Connectome Nominates Target Genes of Inherited Risk Variants from Inflammatory Skin Disorders. <i>Journal of Investigative Dermatology</i> , 2019, 139, 605-614.	0.3	21
22	Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 477-482.	3.3	28
23	Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 564-566.	0.6	83
24	A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. <i>JAAD Case Reports</i> , 2018, 4, 248-250.	0.4	37
25	An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1011-1013.e3.	0.6	12
26	Emerging trends in the treatment of advanced basal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2018, 64, 1-10.	3.4	63
27	A daily skincare regimen with a unique ceramide and filaggrin formulation rapidly improves chronic xerosis, pruritus, and quality of life in older adults. <i>Geriatric Nursing</i> , 2018, 39, 24-28.	0.9	22
28	Evidence-based update on rosacea comorbidities and their common physiologic pathways. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 156-166.	0.6	89
29	Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 372-381.	1.3	144
30	Unintended widespread facial autoinoculation of varicella by home microneedling roller device. <i>JAAD Case Reports</i> , 2018, 4, 546-547.	0.4	7
31	Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1047-1052.	0.6	95
32	Genetic fine-mapping of the lowan SNCA gene triplication in a patient with Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 18.	2.5	28
33	Elder mistreatment training gaps among dermatology resident physicians and opportunity to improve care of a vulnerable population: A cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 360-362.	0.6	1
34	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. <i>JAMA Dermatology</i> , 2017, 153, 285.	2.0	39
35	Initial <i>in vitro</i> functional characterization of serum exosomal microRNAs from patients with metastatic basal cell carcinoma. <i>British Journal of Dermatology</i> , 2017, 177, e187-e190.	1.4	9
36	An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic centre. <i>British Journal of Dermatology</i> , 2017, 177, 1749-1751.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Commentary on Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment. <i>Dermatologic Surgery</i> , 2017, 43, 991-992.	0.4	1
38	Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma. <i>JAMA Dermatology</i> , 2017, 153, 92.	2.0	35
39	Pembrolizumab with or without vismodegib in treating metastatic or unresectable basal cell skin cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9593-TPS9593.	0.8	4
40	Reversible cutaneous side effects of vismodegib treatment. <i>Cutis</i> , 2017, 99, E19-E20.	0.4	0
41	Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinomaâ€”Reply. <i>JAMA Dermatology</i> , 2016, 152, 1173.	2.0	4
42	Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 120.	1.2	27
43	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 113-125.e5.	0.6	133
44	Expanding Our Understanding of Human Skin Aging. <i>Journal of Investigative Dermatology</i> , 2016, 136, 897-899.	0.3	15
45	Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma. <i>JAAD Case Reports</i> , 2016, 2, 13-15.	0.4	33
46	Estimation of individual cumulative ultraviolet exposure using a geographically-adjusted, openly-accessible tool. <i>BMC Dermatology</i> , 2016, 16, 1.	2.1	10
47	A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor. <i>JAMA Dermatology</i> , 2016, 152, 106.	2.0	83
48	Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2016, 152, 527.	2.0	106
49	An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. <i>Clinical Cancer Research</i> , 2016, 22, 1325-1329.	3.2	115
50	Novel Gene Expression Profile of Women with Intrinsic Skin Youthfulness by Whole Transcriptome Sequencing. <i>PLoS ONE</i> , 2016, 11, e0165913.	1.1	11
51	Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2015, 151, 998.	2.0	49
52	Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1021-1026.e8.	0.6	176
53	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 716-728.	5.1	325
54	Management of Cutaneous and Extracutaneous Side Effects of Smoothed Inhibitor Therapy for Advanced Basal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2677-2683.	3.2	17

#	ARTICLE	IF	CITATIONS
55	Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3197-3200.	0.3	20
56	Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma. <i>Cancer Cell</i> , 2015, 27, 342-353.	7.7	337
57	RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. <i>Cancer Research</i> , 2015, 75, 3623-3635.	0.4	133
58	The role of the dermatologist in detecting elder abuse and neglect. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 285-293.	0.6	21
59	Assessment of the Genetic Basis of Rosacea by Genome-Wide Association Study. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1548-1555.	0.3	129
60	Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2138-2141.	0.3	18
61	Patient With Gorlin Syndrome and Metastatic Basal Cell Carcinoma Refractory to Smoothened Inhibitors. <i>JAMA Dermatology</i> , 2014, 150, 877.	2.0	12
62	Two Different Scenarios of Squamous Cell Carcinoma Within Advanced Basal Cell Carcinomas. <i>JAMA Dermatology</i> , 2014, 150, 970.	2.0	50
63	Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. <i>Current Dermatology Reports</i> , 2014, 3, 40-45.	1.1	184
64	Low rate of dermatology outpatient visits in Asian-Americans: an initial survey study for associated patient-related factors. <i>BMC Dermatology</i> , 2014, 14, 13.	2.1	18
65	Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 60-69.	0.6	169
66	Precision medicine and precision therapeutics: Hedgehog signaling pathway, basal cell carcinoma and beyond. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 68-71.	1.6	4
67	Geriatric Dermatology Review: Major Changes in Skin Function in Older Patients and Their Contribution to Common Clinical Challenges. <i>Journal of the American Medical Directors Association</i> , 2013, 14, 724-730.	1.2	57
68	Geriatric dermatology. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 521.e1-521.e10.	0.6	36
69	Geriatric dermatology. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 533.e1-533.e10.	0.6	22
70	Rejuvenation of Gene Expression Pattern of Aged Human Skin by Broadband Light Treatment: A Pilot Study. <i>Journal of Investigative Dermatology</i> , 2013, 133, 394-402.	0.3	42
71	Vismodegib for Periocular and Orbital Basal Cell Carcinoma. <i>JAMA Ophthalmology</i> , 2013, 131, 1591.	1.4	71
72	Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. <i>British Journal of Dermatology</i> , 2013, 169, 673-676.	1.4	29

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2171-2179.	13.9	1,201
74	Stratification of Highest-Risk Patients with Chronic Skin Ulcers in a Stanford Retrospective Cohort Includes Diabetes, Need for Systemic Antibiotics, and Albumin Levels. <i>Ulcers</i> , 2012, 2012, 1-7.	1.0	14
75	An Exploratory Study to Determine the Association Between Assessed Facial Skin Aging and Plasma Isoprostane Levels in Middle-Aged Japanese Women. <i>Dermatologic Surgery</i> , 2012, 38, 462-470.	0.4	2
76	Differential effects of dietary supplements on metabolomic profile of smokers versus non-smokers. <i>Genome Medicine</i> , 2012, 4, 14.	3.6	11
77	A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 333-9.	0.4	11
78	Association of facial skin aging and vitamin D levels in middle-aged white women. <i>Cancer Causes and Control</i> , 2010, 21, 2315-2316.	0.8	12
79	Initial clinical experience using a novel ultraportable negative pressure wound therapy device. <i>Wounds</i> , 2010, 22, 230-6.	0.2	12
80	Alefacept for erosive lichen planus: a case series. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 379-83.	0.4	20
81	A case of argyria after colloidal silver ingestion. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 809-811.	0.7	112
82	Risk factors associated with striae gravidarum. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 881-885.	0.6	124
83	Partnering with a senior living community to optimise teledermatology via full body skin screening during the COVID-19 pandemic: A pilot programme. <i>Skin Health and Disease</i> , 0, , .	0.7	1